CA-AVIATRIX
9.3.2021 15:02:11 CET | Business Wire | Press release
Aviatrix , the cloud network platform, today announced the availability of the 2021 Forrester's Total Economic Impact™ (TEI) Study commissioned by Aviatrix, conducted independently by Forrester Consulting in January 2021. The TEI Study is based on Forrester's in-depth interviews with Aviatrix customers and provides a quantitative, business value justification designed to help IT leaders. It demonstrates a composite cost-savings and business benefits analysis interviewed customers realized by leveraging the Aviatrix cloud network platform and provides a model for determining economic value in any organization.
The complete results of the TEI Study of Aviatrix can be found and downloaded here , where readers will learn how Aviatrix customers leverage more advanced cloud networking, security, and operational visibility for their cloud and multi-cloud network environments, helping them generate new revenue and ensure operational efficiency at significantly lower costs.
Key highlights of the TEI Study on Aviatrix cloud network platform Include:
- Aviatrix pays for itself more than 2x in the span of three years (222% ROI)
- Over $3 million in revenue and margin gains from new and existing customers attributed to multi-cloud readiness and faster time-to-market
- Over $1 million in cost savings from operational efficiency and resource re-allocation
- Over $4 million in business benefits and cost savings over three years
Cloud infrastructure is becoming the norm for many organizations. Decision makers may plan to focus on a single cloud platform, but they often need to support many due to acquisitions, client requirements, or app developer preferences. Each cloud service provider comes with its own processes, native constructs and tools that can slow cloud network operations. The Aviatrix cloud network platform helps organizations automate and control cloud network infrastructure, maintain security compliance, and respond to clients much faster.
Aviatrix customers saw significant benefits after deploying the company’s cloud network platform:
- “Without Aviatrix, it would have taken an extra year and twice the staff” — Sr. Infrastructure Architect, insurance company.
- “We have been able to open new lines of business and keep up with increased demand” — Assistant Director of Cloud Architecture and Engineering, manufacturer.
- “We can shine a light in the dark corners of public cloud [with Aviatrix]” — Senior Cloud Architect, business software and services provider.
- “With Aviatrix, we are saving millions” — Assistant Director of Cloud Architecture and Engineering, manufacturer.
“We’re very pleased with the overall results of the Forrester TEI Study,” said Rod Stuhlmuller, Vice President of Product Marketing at Aviatrix. “The quantifiable data truly highlights the benefits our customers receive using the Aviatrix cloud network platform. Furthermore, our customers achieve these benefits in both single and multi-cloud environments. As more enterprises adopt a multi-cloud strategy, Aviatrix’s market leading solutions will be the foundation for demonstratable economic gains.”
Executive Summary Video of the TEI Study on Aviatrix: (5 mins)
Watch guest speaker Sean Owens, Forrester’s Principal Consultant, and leader of the TEI of Aviatrix cloud network platform study, provide an executive summary of the study’s methodology, key findings, and quantified results. View video here.
About Aviatrix
Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE ), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005348/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom